《中国民航报》、中国民航网 记者胡夕姮 通讯员黄勇 报道：为弘扬新时代民航工匠精神，近日民航福 建监管局成功举办2025年福建民航辖区安全文化竞赛活动。本次竞赛由福建民航工匠精神文化工作室主 办，民航福建空管分局、福州机场、泉州机场、武夷山机场、三明机场、厦航福州分公司、厦航泉州分 公司、海技福州等辖区单位参赛，通过多样化形式全面检验各单位安全管理机制和安全文化建设实际成 效。 竞赛聚焦"双重预防机制建设"与"安全文化评估"两大核心主题，设置台账审查、现场汇报及评委提问等 多样化形式。在双重预防机制建设方面，竞赛充分立足去年试点工作所积累的宝贵经验与坚实基础，大 胆创新、积极拓展，将专业覆盖范围延伸至民航全领域。参赛单位聚焦"落地实施"这一关键核心目标， 全力打通安全管理与运行管理之间的"最后一公里"，围绕各自专业领域运用双重预防机制开展案例分 析，包括"违禁物品进入控制区""漏拔起落架安全销""机场桥载电源缆线损伤航空器"等典型案例，为辖 区双重预防机制的全面深入落地提供了极具借鉴意义的宝贵案例经验。 安全文化评估环节紧扣民航规范标准要求，融入"精益文化"理念，引导各单位从"安全第一""生命至 上""忧患文 ...

Core Viewpoint - The article emphasizes the importance of building a distinctive financial culture in the public fund industry, aligning with the principles outlined in the 20th National Congress of the Communist Party of China and the 2023 Central Financial Work Conference [3][4]. Summary by Sections Introduction - The public fund industry has become a significant force in China's financial system, with assets reaching 35.08 trillion yuan and over 13,000 products by July 2025 [2]. - Challenges include a focus on scale over quality, product homogeneity, and inadequate investor service [2]. Core Values of Public Fund Corporate Culture - **Trust Responsibility**: The foundation of corporate culture must focus on protecting investor interests, ensuring accurate risk disclosures, and adhering to investment strategies [4]. - **Long-term Value**: The culture should promote a long-term investment perspective, moving away from short-term speculation and emphasizing thorough research [5][6]. - **Professional Adaptation**: The culture must balance professional capabilities with compliance, innovating within the framework of serving the real economy [7]. Cross-Industry Cultural Insights - **Lean Culture from Manufacturing**: Emphasizes process optimization and efficiency, which can be adapted to enhance research and product design in public funds [9][11]. - **Risk Control Culture from Banking**: Advocates for comprehensive risk management practices that can strengthen the public fund industry's cautious approach [12][15]. - **User-Centric Culture from Internet**: Focuses on understanding investor needs and providing tailored services, addressing the issue of service homogeneity in public funds [16][18]. Current Status and Optimization Paths - **Current Status**: There is an awakening awareness of cultural construction, but issues of "virtualization" and "disconnection" remain prevalent [19]. - **Optimization Path**: Emphasizes the need for deep integration of culture and business processes, with clear principles for adapting cross-industry experiences [20][21]. Conclusion - The article concludes that the public fund industry can benefit from cross-industry cultural experiences, provided they are adapted rather than copied, to effectively address current challenges and enhance quality development [21].

Financial Data and Key Metrics Changes - Organic revenue grew by 6% year over year, with adjusted EBITDA margin expanding by 400 basis points [7][26][28] - Total revenue for the second quarter was $143 million, reflecting a 5% year over year increase on a reported basis and 6% on an organic basis [27][29] - Non-GAAP EPS for the quarter was $0.05, with adjusted EBITDA margin at 10% [28][29] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $80 million, up 8% year over year, driven by strong performance in sample repository solutions and core products [30] - Multiomics revenue was $64 million, with a growth of 2% on a reported basis and 3% on an organic basis, primarily driven by next-generation sequencing [31][32] Market Data and Key Metrics Changes - North America experienced a general slowdown, particularly in Sanger sequencing, which saw an 18% year over year decline [34] - China showed strength with 5% organic revenue growth, despite geopolitical tensions [32][71] Company Strategy and Development Direction - The company is focused on operational excellence and reducing complexity through the Azenta Business System [12][13] - Plans for potential tuck-in acquisitions are being evaluated to accelerate revenue growth and margin expansion [11][12] - The company aims to maintain a high bar for capital deployment, including potential stock buybacks if valuation disconnects persist [12][88] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macro environment, including NIH funding cuts and tariffs, but expressed confidence in countermeasures to mitigate impacts [9][10][58] - The company remains committed to its full-year guidance of organic revenue growth between 3% and 5% and adjusted EBITDA margin expansion of 300 basis points [8][36] Other Important Information - The sale process for B Medical Systems is ongoing, with expectations for an announcement in the second half of fiscal year 2025 [8][25] - The company ended the quarter with $540 million in cash and no debt outstanding [28][36] Q&A Session Summary Question: Guidance and Growth Cadence - Analyst inquired about the growth cadence in the second half of the year and the impact of NIH funding on guidance [40] - Management confirmed that the guidance remains unchanged and expects the revenue profile to align with prior years [44][45] Question: Leadership Transition in SMS - Analyst asked about the leadership transition in SMS and future leadership plans [46] - Management indicated that the CEO is directly involved in running the SMS business during the transition [47][48] Question: NIH Funding Headwind - Analyst sought clarification on the assumptions behind the 1% headwind from NIH funding [52] - Management explained that they have countermeasures in place and are actively engaging with academic customers to mitigate risks [53][58] Question: Free Cash Flow and Margins - Analyst questioned the sustainability of free cash flow performance and margin expectations [59] - Management expressed confidence in achieving the long-term target of $100 million in free cash flow [60][62] Question: Sales Force Structure and ABS - Analyst inquired about the sales force structure under the Azenta Business System [67] - Management confirmed that a regional go-to-market model has been established and investments in sales are ongoing [68] Question: Gene Synthesis Trends - Analyst asked for insights on gene synthesis trends and customer dynamics [78] - Management noted a temporary pause in large pharma programs but indicated positive trends in recent bookings [80][81] Question: Capital Deployment Strategy - Analyst sought clarity on the balance between buybacks and M&A opportunities [83] - Management emphasized a holistic approach to capital deployment, focusing on long-term shareholder value [86][88] Question: Customer Insights and Order Trends - Analyst asked about potential order pull-forward due to tariffs and NGS ordering trends [93] - Management highlighted increased outsourcing opportunities and positive customer feedback on quality and delivery [98][100]